Overweight in high-quality government bonds with a core allocation to equities Lean toward Asia where greater relative value exists across equities and bonds DUBAI, UAE, July 4, 2023 /PRNewswire/ — Standard Chartered announced today its Global Market Outlook report for the second half of…
Month: July 2023
TSXV: PGZ OTCQB: PGZFF Highest-grade copper-gold mineralization in all holes at Cañada Honda drilled to date Mineralization open in all directions Gravity anomaly more than 2km long Cañada Honda one of more than 14 Escacena gravity anomalies VANCOUVER, BC, July 4, 2023 /PRNewswire/ — Pan…
TSXV: PGZ OTCQB: PGZFF Highest-grade copper-gold mineralization in all holes at Cañada Honda drilled to date Mineralization open in all directions Gravity anomaly more than 2km long Cañada Honda one of more than 14 Escacena gravity anomalies VANCOUVER, BC, July 4, 2023 /PRNewswire/ – Pan…
NEW YORK, July 4, 2023 /PRNewswire/ — The precision medicine market size is estimated to grow by USD 54.07 billion from 2022 to 2027, according to Technavio. The market is estimated to grow at a CAGR of 11.32% during the forecast period. Technavio estimates that the growth momentum will…
-La Comisión Europea otorga Autorización de Comercialización Condicional para los comprimidos LYTGOBI® de Taiho para el tratamiento de adultos con colangiocarcinoma LYTGOBI es el primer inhibidor de FGFR de unión irreversible en la Unión Europea para su uso en el tratamiento de pacientes…
LYTGOBI ist der erste irreversibel bindende FGFR-Inhibitor in der Europäischen Union (European Union), der zur Behandlung von Patienten mit Cholangiokarzinom eingesetzt wird ZUG, Schweiz, 4. Juli 2023 /PRNewswire/ — Taiho Oncology Europe GmbH und Taiho Pharmaceutical Co. Ltd. gaben heute…
LYTGOBI est le premier inhibiteur du FGFR à liaison irréversible dans l’Union européenne pour le traitement des patients atteints de cholangiocarcinome ZUG, Suisse, 4 juillet 2023 /PRNewswire/ — Taiho Oncology Europe GmbH et Taiho Pharmaceutical Co., Ltd. ont annoncé aujourd’hui que la…
LYTGOBI is the first irreversibly binding FGFR inhibitor in the European Union for use in the treatment of patients with cholangiocarcinoma ZUG, Switzerland, July 4, 2023 /PRNewswire/ — Taiho Oncology Europe GmbH and Taiho Pharmaceutical Co., Ltd., announced today that the European…
Recently launched iOS app aims to resolve issues concerning both the performance and security of modern devices STROVOLOS, Cyprus, July 4, 2023 /PRNewswire/ — While technology keeps advancing and achieving new heights, some age-old problems persist and keep bothering many users all…
DUBLIN, July 4, 2023 /PRNewswire/ — The “Saudi Arabia Data Center Market – Investment Analysis & Growth Opportunities 2023-2028” report has been added to ResearchAndMarkets.com’s offering. The Saudi Arabia data center market is expected to reach a value of $2.08 billion by 2028 from…